Geplaatst op 21 September 2019.
As per the 2018 World Alzheimer Report, in the world develops dementia every three seconds. There were an estimated 50 million people worldwide living with dementia in 2017 — a number that will almost double every 20 years, reaching 131.5 million in 2050.
Alzheimer’s disease and other dementias are a major and increasing global health challenge, with 40–50 million people currently living with dementia. The number of individuals living with dementia is increasing, negatively affecting families, communities, and health-care systems around the world.
Every year on September 21, World Alzheimer’s Day is observed. Alzheimer is a progressive disorder, destroys memory and leads to degeneration of cells impacting important mental function. Alzheimer causes impairment of speech and memory areas which is riskier than forgetfulness.
To date, the evidence researches have observed from the use of Photobiomodulation to treat Alzheimer has been significant and very promising. Read here an important article from the Journal of Biosciences and Medicines in which you can read that many studies have been done into the effect of photobiomodulation on Alzheimer’s. Why are there many positive effects?
Photobiomodulation (PBM), also known as low-level light therapy (LLLT), is a biostimulation technique that shows promise in treating a number of conditions, including dementia and Alzheimer’s disease. The most well investigated mechanism of action of PBM is its fundamental effect on mitochondrial function. The process increases the amount of ATP produced, as well as cyclic adenosine monophosphate (cAMP) and reactive oxygen species (ROS).
The increase in ATP increases the activity of ion channels, regulate cAMP and calcium, which results in the stimulation of diverse biological cascades and activate up to 110 genes, which themselves lead to the prolongation of the production of energy by the mitochondria.
The increase of ROS formation is transient and at low levels. This is thought to activate mitochondrial signalling pathways that have antioxidant, anti-apoptotic and cytoprotective effects on cells. A number of cellular mechanisms are in involved in sensing excessive levels of ROS, and respond by activating transcription factors which produce increased antioxidant defenses, preserving homeostasis.
In addition to increasing levels of ATP and cAMP, it has been observed that PBM results in an increase in nitric oxide (NO) levels, dissociated from the mitochondria where the photons are absorbed  . The dissociation of NO from cytochrome c oxidase (CCO) leads to the further enhancement of ATP production and acts as a vasodilator as well as a dilator of lymphatic flow, and can signal to activate a number of beneficial cellular pathways  .
The points raised here support PBM as a promising therapy for AD, and it now comes to how to put theory into practice.
Multiple pathway mechanisms stemming from delivering low energy near infrared (NIR) light to the mitochondria in brain cells. The mechanisms involve the activation of gene transcription that lead to neuronal recovery, removal of toxic plaques, normalizing network oscillations that can lead to improved cognition and functionality.
Laeq & Photobiomodulation
Laeq is a tool based on low levellaser / photobiomodulation and helps to recharge and stimulate the mitochondria, improves metabolism, strengthens the immune system, increases cognitive abilities and more. It is not a tool that heals Alzheimer’s. By applying the Laeq, according to the research, it can play an important role in preventing this terrible disease. PBM can be applied by anyone without side effects and has multiple health and lifestyle advantages.
The theme for World Alzheimer’s Month 2019 is raising awareness and challenging stigma.
Our theme for the world is raising awareness for #photobiomodulation as a healthy method to stay healthy, become healthier and get fitter. Thousands of researches show the benefits for all.